+ Watch SNTS
on My Watchlist
A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.
At this point, everyone is assuming the worst case scenario with generic Zegerid regarding Par Pharma, and this is priced into the stock....The company has over $1.50/share in cash alone....At current prices, the rest of the company flagship without the cash is priced at $72 million.....They will have $50 million in Glumetza sales this year, Merck just launched Zegerid OTC 1 1/2 months ago (in which SNTS will receive royalties moving forward), plus two late stage III drugs.....(All priced at $72 million), and they will still have $100 + million in Zegerid prescription sales this year........seems cheap.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions